Following this sale, Laponis holds 110,096 shares of Twist Bioscience. The filing notes that the sale was made to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by the company's equity incentive plans. According to InvestingPro analysis, Twist Bioscience maintains strong financial health with a robust current ratio of 4.88 and has achieved impressive revenue growth of 27.69% over the last twelve months. For deeper insights into TWST's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro. According to InvestingPro analysis, Twist Bioscience maintains strong financial health with a robust current ratio of 4.88 and has achieved impressive revenue growth of 27.69% over the last twelve months. For deeper insights into TWST's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
Following this sale, Laponis holds 110,096 shares of Twist Bioscience. The filing notes that the sale was made to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by the company's equity incentive plans.
In other recent news, Twist Bioscience Corporation (NASDAQ:TWST) has demonstrated impressive financial performance, with Q4 revenues increasing by 27% to $84.7 million and total annual revenue growth of 28%, reaching $330 million. The company's gross margin guidance for the quarter was exceeded, achieving 45.1%, and an annual gross margin improvement to 42.6% was noted. The company's initial guidance for FY25 anticipates revenue growth between 17% to 20% year-over-year, largely driven by the Next (LON:NXT) Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors.
Several analyst firms have provided their take on Twist Bioscience's recent developments. Baird maintained an Outperform rating on the company and increased the price target to $48.00, while TD Cowen reaffirmed a Buy rating with a price target of $58.00. Scotiabank (TSX:BNS) also maintained a Sector Outperform rating and raised its price target for the company to $54.
These adjustments come in the wake of Twist Bioscience's strong performance in the fiscal year 2024 and the company's promising outlook for the fiscal year 2025. The company's robust financial position was further bolstered by a $15 million upfront payment received from Xoma (NASDAQ:XOMA) as part of a royalty purchase agreement. These are among the recent developments shaping the future of Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.